Roche Reports Third-Quarter 2026 Sales Results
Pharmaceutical sales exceeded consensus and analyst estimates, while diagnostics fell short of market expectations. Roche confirmed its full-year guidance; pharma results included a one-time Japan inventory effect tied to a new ERP system.
Roche Holding AG said third-quarter 2026 sales in its pharmaceutical division topped consensus and analyst estimates, while its diagnostics division fell short of market expectations. The company kept its existing full-year financial guidance unchanged. Analysts said a one-time inventory effect associated with the rollout of a new ERP system in Japan partly supported pharmaceutical sales.